CN103923640B - A kind of fluorescence probe and application thereof of benzothiazoles identification hydrogen sulfide - Google Patents
A kind of fluorescence probe and application thereof of benzothiazoles identification hydrogen sulfide Download PDFInfo
- Publication number
- CN103923640B CN103923640B CN201410179994.8A CN201410179994A CN103923640B CN 103923640 B CN103923640 B CN 103923640B CN 201410179994 A CN201410179994 A CN 201410179994A CN 103923640 B CN103923640 B CN 103923640B
- Authority
- CN
- China
- Prior art keywords
- hydrogen sulfide
- fluorescent probe
- benzothiazole
- hydroxyphenyl
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229910000037 hydrogen sulfide Inorganic materials 0.000 title claims abstract description 49
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 239000000523 sample Substances 0.000 title abstract description 13
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 23
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims abstract description 10
- MVVGSPCXHRFDDR-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)phenol Chemical group OC1=CC=CC=C1C1=NC2=CC=CC=C2S1 MVVGSPCXHRFDDR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 claims abstract description 5
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 5
- PBOPJYORIDJAFE-UHFFFAOYSA-N 2,4-dinitrobromobenzene Chemical compound [O-][N+](=O)C1=CC=C(Br)C([N+]([O-])=O)=C1 PBOPJYORIDJAFE-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 3
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 claims description 3
- GUNPMLPBRKEPAW-UHFFFAOYSA-N [Na].OC1=C(C=CC=C1)C=1SC2=C(N1)C=CC=C2 Chemical group [Na].OC1=C(C=CC=C1)C=1SC2=C(N1)C=CC=C2 GUNPMLPBRKEPAW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000011158 quantitative evaluation Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 10
- 238000001514 detection method Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 238000002189 fluorescence spectrum Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 2
- 239000012847 fine chemical Substances 0.000 abstract description 2
- 239000012535 impurity Substances 0.000 abstract description 2
- 239000011159 matrix material Substances 0.000 abstract description 2
- 238000007363 ring formation reaction Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- -1 colorimetry Chemical compound 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000001917 fluorescence detection Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000006241 metabolic reaction Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OJOLFAIGOXZBCI-UHFFFAOYSA-N 3-mercaptopyruvic acid Chemical compound OC(=O)C(=O)CS OJOLFAIGOXZBCI-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004007 neuromodulation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000002602 strong irritant Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
一种苯并噻唑类识别硫化氢的荧光探针及其应用,其属于精细化工领域。这种荧光探针为2-(2-羟基苯基)苯并噻唑衍生物;按照比例将2-(2-羟基苯基)苯并噻唑与碳酸钾、2,4-二硝基溴苯混合,最后采用硅胶色谱法进行纯化,得荧光探针。该荧光探针及相应硫化氢含量检测过程不会受生物体系基质及杂质的干扰,可用于各种生物体系中硫化氢含量的定量测定。这种应该探针具有高特异性,可以与硫化氢特异性环化后水解,即醚键断裂的水解产物;廉价易得,可经化学合成获得,合成工艺简单易行;灵敏度高,具有良好的荧光发射光谱特性(450~500nm),通过绘制标准曲线进行硫化氢定量测定。A fluorescent probe for recognizing hydrogen sulfide by benzothiazoles and an application thereof belong to the field of fine chemical industry. This fluorescent probe is 2-(2-hydroxyphenyl)benzothiazole derivative; mix 2-(2-hydroxyphenyl)benzothiazole with potassium carbonate and 2,4-dinitrobromobenzene in proportion , and finally purified by silica gel chromatography to obtain the fluorescent probe. The fluorescent probe and the corresponding hydrogen sulfide content detection process will not be interfered by the matrix and impurities of the biological system, and can be used for the quantitative determination of the hydrogen sulfide content in various biological systems. This should probe has high specificity and can be hydrolyzed after specific cyclization with hydrogen sulfide, that is, the hydrolyzed product of ether bond breaking; it is cheap and easy to obtain, and can be obtained by chemical synthesis, and the synthesis process is simple and easy; it has high sensitivity and good Fluorescence emission spectrum characteristics (450-500nm), quantitative determination of hydrogen sulfide by drawing a standard curve.
Description
技术领域technical field
本发明涉及一种苯并噻唑类识别硫化氢的荧光探针及其应用,其属于精细化工领域。The invention relates to a fluorescent probe for recognizing hydrogen sulfide by benzothiazoles and an application thereof, belonging to the field of fine chemical industry.
背景技术Background technique
几个世纪以来,硫化氢(H2S)被认为是由地质活动或微生物作用产生的一种有毒物质。这种无色、可燃的气体具有令人恶心的臭鸡蛋气味,并可对哺乳动物的眼睛及呼吸系统产生强烈的刺激作用。吸入过量的硫化氢气体则可导致意识丧失、呼吸衰竭、心跳停止等生理反应,吸收量过大时可导致死亡。另一方面,现在越来越多研究己经开始挑战这种传统的观念:哺乳动物自身可以在受控的条件下产生硫化氢,并认为硫化氧对于维持正常的生理功能具有重要作用。在晡乳动物体内硫化氢可由非酶作用产生,包括体内硫库的释放及聚硫化合物的代谢等。也可由多种酶参与催化合成,包括胱硫醚-聚合酶(CBS)、胱硫醚-裂解酶(CSE)、半胱氨酸转移酶及疏基丙酮酸转硫酶。这些酶可通过不同的反应催化含硫的生物分子如半胱氨酸、高半光氨酸等产生硫化氢。这几种酶出现在心脏、脉管系统、脑、肾脏、肺及胰腺等多种器官的组织中,说明了硫化氧在哺乳动物体内的分布很广泛。For centuries, hydrogen sulfide (H 2 S) was considered to be a toxic substance produced by geological activities or microbial action. This colorless, flammable gas has a disgusting smell of rotten eggs and is a strong irritant to the eyes and respiratory system of mammals. Excessive inhalation of hydrogen sulfide gas can lead to loss of consciousness, respiratory failure, cardiac arrest and other physiological reactions, and excessive absorption can lead to death. On the other hand, more and more studies have begun to challenge this traditional concept: mammals can produce hydrogen sulfide under controlled conditions, and it is believed that oxygen sulfide plays an important role in maintaining normal physiological functions. Hydrogen sulfide can be produced by non-enzymatic actions in aspirin mammals, including the release of sulfur pools in the body and the metabolism of polysulfide compounds. It can also be catalyzed by a variety of enzymes, including cystathionine-polymerase (CBS), cystathionine-lyase (CSE), cysteine transferase and mercaptopyruvate transsulfurase. These enzymes can catalyze sulfur-containing biomolecules such as cysteine and homocysteine to produce hydrogen sulfide through different reactions. These enzymes appeared in the tissues of various organs such as the heart, vasculature, brain, kidney, lung, and pancreas, indicating that oxygen sulfide is widely distributed in mammals.
在哺乳动物体内,硫化氢可与下游蛋白质通过转译后的半胱氨酸发生巯基化反应并连接在血红素的铁中心上。这一过程将控制多种生理反应,包括局部缺血再灌注引起的损伤、血管舒张、细胞死亡、血管生成、神经调节、炎症治疗、胰岛素信号传导和氧气应激等。此外,硫化氢也作为活性氧的抗氧化剂或清除剂而发挥作用。但是H2S的浓度水平不正常己被证实与很多疾病有关。这些开创性的实验已经表明硫化氢是一种重要的生理调控气体而不单单是一种污染物。硫化氢复杂的生理角色及潜在的治疗应用促使科研工作者提出新的方法用于监测硫化氢的产生、流通和在不同细胞、组织及器官内的消耗过程。In mammals, hydrogen sulfide can undergo thiol reaction with downstream proteins through post-translational cysteine and connect to the iron center of heme. This process will control multiple physiological responses, including ischemia-reperfusion-induced injury, vasodilation, cell death, angiogenesis, neuromodulation, inflammation therapy, insulin signaling, and oxygen stress, among others. In addition, hydrogen sulfide also acts as an antioxidant or scavenger for reactive oxygen species. However, the abnormal concentration level of H 2 S has been confirmed to be related to many diseases. These pioneering experiments have shown that hydrogen sulfide is an important physiological regulating gas and not just a pollutant. The complex physiological roles and potential therapeutic applications of hydrogen sulfide have prompted researchers to propose new methods for monitoring the production, circulation and consumption of hydrogen sulfide in different cells, tissues and organs.
传统用于检测硫化氢的方法包括比色测定法、极谱传感法和气相色谱法通常会引起待测样品的损伤,或是根本不能实现对生物体内硫化物的检测。荧光分子探针提供了一个引人注的方法,由于其具有细胞膜通透性和高选择性,因而可实现在生物体系中对硫化氢及其他生物小分子的检测。荧光分析法将为研究硫化氢的生理功能提供重要的生物信息。设近两年来,有关硫化氢光检测的报道受到研究工作者的高度关注。Traditional methods for the detection of hydrogen sulfide, including colorimetry, polarographic sensing and gas chromatography, usually cause damage to the sample to be tested, or cannot detect sulfide in organisms at all. Fluorescent molecular probes provide an attractive method for the detection of hydrogen sulfide and other small biomolecules in biological systems due to their membrane permeability and high selectivity. Fluorescence analysis will provide important biological information for studying the physiological function of hydrogen sulfide. In the past two years, the reports on the optical detection of hydrogen sulfide have attracted great attention of researchers.
本发明提供了一类2-(2-羟基苯基)苯并噻唑衍生物用于特异性识别硫化氢(H2S)的探针,其与硫化氢水解后可生成具有荧光属性的水解产物。该反应具有高选择性、高灵敏度、反应迅速的特点。The invention provides a class of 2-(2-hydroxyphenyl)benzothiazole derivatives as probes for specifically recognizing hydrogen sulfide (H 2 S), which can generate hydrolyzed products with fluorescent properties after hydrolysis with hydrogen sulfide . The reaction has the characteristics of high selectivity, high sensitivity and rapid response.
发明内容Contents of the invention
本发明的目的在于提供一种识别硫化氢的特异性荧光探针,该探针本身具有微弱的荧光,与硫化氢(H2S)反应后产物具有极强的荧光属性。利用该探针反应可对多种生物样本中硫化氢(H2S)含量进行定量评价。The purpose of the present invention is to provide a specific fluorescent probe for recognizing hydrogen sulfide. The probe itself has weak fluorescence, and the product reacted with hydrogen sulfide (H 2 S) has extremely strong fluorescence properties. The probe reaction can be used to quantitatively evaluate the content of hydrogen sulfide (H 2 S) in various biological samples.
本发明的技术方案为:一种苯并噻唑类识别硫化氢的荧光探针,所述荧光探针为2-(2-羟基苯基)苯并噻唑衍生物,其结构式如下:The technical solution of the present invention is: a benzothiazole-based fluorescent probe for recognizing hydrogen sulfide, the fluorescent probe is a 2-(2-hydroxyphenyl) benzothiazole derivative, and its structural formula is as follows:
所述荧光探针的制备方法包括如下步骤:The preparation method of described fluorescent probe comprises the steps:
(1)按照2-(2-羟基苯基)苯并噻唑:2,4-二硝基溴苯:碳酸钾摩尔比为1:1~2:2~3的比例加入到反应瓶中,加入乙腈,控制反应温度在40~80℃,搅拌8-12h;(1) According to the molar ratio of 2-(2-hydroxyphenyl)benzothiazole:2,4-dinitrobromobenzene:potassium carbonate is 1:1~2:2~3, add it into the reaction flask, add Acetonitrile, control the reaction temperature at 40~80°C, stir for 8-12h;
(2)将上述反应液经过减压除去溶剂,残留的固体采用硅胶色谱法进行纯化,采用乙酸乙酯:正己烷体积比为1:3的洗脱剂进行洗脱,得荧光探针(2) The solvent was removed from the above reaction solution under reduced pressure, and the residual solid was purified by silica gel chromatography, and eluted with an eluent with a volume ratio of ethyl acetate:n-hexane of 1:3 to obtain a fluorescent probe
所述荧光探针应用于生物样本中硫化氢含量的定量评价。该探针作为硫化氢的特异性探针,发生水解反应,通过定量检测水解产物的荧光强度来测定细胞中硫化氢的含量;具体测定方法为:The fluorescent probe is applied to quantitative evaluation of hydrogen sulfide content in biological samples. As a specific probe for hydrogen sulfide, the probe undergoes a hydrolysis reaction, and the content of hydrogen sulfide in the cell is determined by quantitatively detecting the fluorescence intensity of the hydrolyzed product; the specific determination method is:
体系中以2-(2-羟基苯基)苯并噻唑衍生物作为特异性探针;探针浓度选择1/~10μM;在PBS或Tris-HCl等常用缓冲液:二甲基亚砜混合溶液(体积比7:3)中,反应温度为20℃至60℃之间,优选37℃为最优反应时间;反应体系pH介于5.5~10.5之间,优选pH7.4为最优反应pH值;反应时间为5~120分钟;测定水解产物荧光强度作为硫化氢含量的评价指标。In the system, 2-(2-hydroxyphenyl)benzothiazole derivatives are used as specific probes; the probe concentration is 1/~10 μM; common buffers such as PBS or Tris-HCl: dimethyl sulfoxide mixed solution (Volume ratio 7:3), the reaction temperature is between 20°C and 60°C, preferably 37°C is the optimal reaction time; the pH of the reaction system is between 5.5 and 10.5, preferably pH 7.4 is the optimal reaction pH value ; The reaction time is 5-120 minutes; The fluorescence intensity of the hydrolyzate is measured as the evaluation index of the hydrogen sulfide content.
探针本身具有微弱荧光,其水解产物均具有极强的荧光,可采用荧光检测器实现产物及底物的快速灵敏检测;荧光检测条件为:激发波长300nm,在450~500nm进行荧光发射谱的检测。The probe itself has weak fluorescence, and its hydrolyzed products have extremely strong fluorescence. Fluorescence detectors can be used to realize rapid and sensitive detection of products and substrates; the fluorescence detection conditions are: excitation wavelength 300nm, fluorescence emission spectrum at 450~500nm detection.
本发明的有益效果为:这种荧光探针为2-(2-羟基苯基)苯并噻唑衍生物;按照比例将2-(2-羟基苯基)苯并噻唑钠盐与碳酸钾、2,4-二硝基溴苯混合,加入N,N-二甲基甲酰胺,加热,最后采用硅胶色谱法进行纯化,得荧光探针。该荧光探针及相应硫化氢含量检测过程不会受生物体系基质及杂质的干扰,可用于各种生物体系中硫化氢含量的定量测定。这种应该探针具有高特异性,可以与硫化氢特异性环化后水解,即醚键断裂的水解产物;廉价易得,可经化学合成获得,合成工艺简单易行;灵敏度高,具有良好的荧光发射光谱特性(450~500nm),通过绘制标准曲线进行硫化氢定量测定。The beneficial effects of the present invention are: the fluorescent probe is 2-(2-hydroxyphenyl)benzothiazole derivative; 2-(2-hydroxyphenyl)benzothiazole sodium salt and potassium carbonate, 2 , mixed with 4-dinitrobromobenzene, added N, N-dimethylformamide, heated, and finally purified by silica gel chromatography to obtain a fluorescent probe. The fluorescent probe and the corresponding hydrogen sulfide content detection process will not be interfered by the matrix and impurities of the biological system, and can be used for the quantitative determination of the hydrogen sulfide content in various biological systems. This should probe has high specificity and can be hydrolyzed after specific cyclization with hydrogen sulfide, that is, the hydrolyzed product of ether bond breaking; it is cheap and easy to obtain, and can be obtained by chemical synthesis, and the synthesis process is simple and easy; it has high sensitivity and good Fluorescence emission spectrum characteristics (450-500nm), quantitative determination of hydrogen sulfide by drawing a standard curve.
附图说明Description of drawings
图1是2-(2(2,4-二硝基苯氧基))苯并噻唑的1H-NMR谱图。Fig. 1 is a 1 H-NMR spectrum of 2-(2(2,4-dinitrophenoxy))benzothiazole.
图2是2-(2(2,4-二硝基苯氧基))苯并噻唑的13C-NMR谱图。Fig. 2 is a 13 C-NMR spectrum of 2-(2(2,4-dinitrophenoxy))benzothiazole.
图3是2-(2(2,4-二硝基苯氧基))苯并噻唑的高分辨质谱。Figure 3 is the high resolution mass spectrum of 2-(2(2,4-dinitrophenoxy))benzothiazole.
图4是荧光探针与不同物质反应后荧光变化结果。Fig. 4 is the result of fluorescence change after the fluorescent probe reacts with different substances.
图5是荧光探针与不同浓度硫化氢反应后荧光强度变化曲线。Fig. 5 is the fluorescence intensity change curve after the fluorescent probe reacts with different concentrations of hydrogen sulfide.
图6是荧光探针与硫化氢反应荧光强度变化与时间的关系。Fig. 6 is the relationship between the fluorescence intensity change and the time when the fluorescent probe reacts with hydrogen sulfide.
图7是共聚焦成像图。Figure 7 is a confocal imaging diagram.
具体实施方式detailed description
下面的实施例将对本发明予以进一步的说明,但并不因此而限制本发明。The following examples will further illustrate the present invention, but do not limit the present invention thereby.
实施例12-(2(2,4-二硝基苯氧基))苯并噻唑的化学合成Chemical synthesis of embodiment 12-(2(2,4-dinitrophenoxy))benzothiazole
(1)将0.5mmol的2-(2-羟基苯基)苯并噻唑和0.625mmol碳酸钾、0.5mmol2,4-二硝基溴苯溶于10mL乙腈,在80℃反应4h;(1) Dissolve 0.5mmol of 2-(2-hydroxyphenyl)benzothiazole, 0.625mmol of potassium carbonate and 0.5mmol of 2,4-dinitrobromobenzene in 10mL of acetonitrile, and react at 80°C for 4h;
(2)将反应液进行减压蒸馏;(2) The reaction solution is subjected to vacuum distillation;
(3)固体采用硅胶色谱法进行纯化,采用乙酸乙酯-正己烷(1:3v/v)进行洗脱,得淡黄色固体,表征结果见图1、图2和图3。1HNMR(400MHz,DMSO)δ8.98(d,J=2.8Hz,1H),8.50(dd,J=7.9,1.6Hz,1H),8.42(dd,J=9.3,2.8Hz,1H),8.11(d,J=8.0Hz,1H),8.04(d,J=8.1Hz,1H),7.79–7.68(m,1H),7.66–7.51(m,2H),7.47(dd,J=14.4,7.5Hz,2H),7.24(d,J=9.3Hz,1H).13CNMR(100MHz,CDCl3)δ160.87,155.66,152.67,150.68,141.78,139.54,135.50,132.51,131.30,128.99,127.45,126.60,126.56,125.72,123.46,122.25,122.13,121.52,117.80.HRMScalcdforC16H14NO5+([M+H]+)394.0492,found394.0501。(3) The solid was purified by silica gel chromatography, and eluted with ethyl acetate-n-hexane (1:3 v/v) to obtain a light yellow solid. The characterization results are shown in Figure 1, Figure 2 and Figure 3. 1 HNMR(400MHz,DMSO)δ8.98(d,J=2.8Hz,1H),8.50(dd,J=7.9,1.6Hz,1H),8.42(dd,J=9.3,2.8Hz,1H),8.11 (d,J=8.0Hz,1H),8.04(d,J=8.1Hz,1H),7.79–7.68(m,1H),7.66–7.51(m,2H),7.47(dd,J=14.4,7.5 Hz,2H),7.24(d,J=9.3Hz,1H).13CNMR(100MHz,CDCl3)δ160.87,155.66,152.67,150.68,141.78,139.54,135.50,132.51,131.30,128.99,127.45,126.60,121 , 123.46, 122.25, 122.13, 121.52, 117.80. HRMS calcd for C16H14NO5+([M+H]+) 394.0492, found 394.0501.
实施例22-(2(2,4-二硝基苯氧基))苯并噻唑对于不同物质的选择性Example 22-(2(2,4-dinitrophenoxy))benzothiazole selectivity for different substances
(1)预先准备99μl代谢反应体系,包括pH7.4的PBS缓冲液(10mM):二甲基亚砜(体积比7:3),氟离子(100μM)、氯离子(50μM)、溴离子(100μM)、碘离子(100μM)、钠离子(100μM)、钾离子(100μM)、钙离子(100μM)、镁离子(100μM)、硝酸根离子(100μM)、硫氢化钠(100μM);(1) Prepare 99 μl metabolic reaction system in advance, including PBS buffer (10 mM) at pH 7.4: dimethyl sulfoxide (volume ratio 7:3), fluoride ion (100 μM), chloride ion (50 μM), bromide ion ( 100μM), iodide ion (100μM), sodium ion (100μM), potassium ion (100μM), calcium ion (100μM), magnesium ion (100μM), nitrate ion (100μM), sodium hydrosulfide (100μM);
(2)向反应体系中加入1μl终浓度为10μM2-(2(2,4-二硝基苯氧基))苯并噻唑起始反应;(2) Add 1 μl of 2-(2(2,4-dinitrophenoxy))benzothiazole at a final concentration of 10 μM to the reaction system to initiate the reaction;
(3)30min后,进行荧光检测(λEx=300nm,λEm=458nm);计算各体系中荧光强度(见图4)。(3) After 30 minutes, perform fluorescence detection (λ Ex =300nm, λ Em =458nm); calculate the fluorescence intensity in each system (see Figure 4).
实施例32-(2(2,4-二硝基苯氧基))苯并噻唑与硫化氢浓度线性关系Example 32-(2(2,4-dinitrophenoxy))benzothiazole and hydrogen sulfide concentration linear relationship
(1)预先准备99μl代谢反应体系,包括pH7.4的PBS缓冲液(10mM):二甲基亚砜(体积比7:3),硫化氢(0-100μM),于37℃条件下反应30分钟;(1) Prepare 99μl metabolic reaction system in advance, including PBS buffer (10mM) at pH 7.4: dimethyl sulfoxide (volume ratio 7:3), hydrogen sulfide (0-100μM), react at 37°C for 30 minute;
(2向反应体系中加入1μl终浓度为10μM2-(2(2,4-二硝基苯氧基))苯并噻唑起始反应;(2) Add 1 μl of 2-(2(2,4-dinitrophenoxy))benzothiazole at a final concentration of 10 μM to the reaction system to initiate the reaction;
(3)30min后,进行荧光检测(λEx=300nm,λEm=458nm);计算各体系中荧光强度,建立荧光强度与硫化氢浓度标准曲线(见图5);标准曲线为y=3695.9x-373.09,R2=0.9931,其中,y代表458nm处荧光强度,x代表硫氢化钠浓度(肼浓度在0uM至100uM之间线性关系满足)。(3) After 30 minutes, perform fluorescence detection (λ Ex =300nm, λ Em =458nm); calculate the fluorescence intensity in each system, and establish a standard curve of fluorescence intensity and hydrogen sulfide concentration (see Figure 5); the standard curve is y=3695.9x -373.09, R2=0.9931, where, y represents the fluorescence intensity at 458nm, and x represents the concentration of sodium hydrosulfide (the linear relationship between the concentration of hydrazine is satisfied between 0uM and 100uM).
实施例42-(2(2,4-二硝基苯氧基))苯并噻唑为探针与硫化氢反应荧光强度变化与时间的关系Example 42-(2(2,4-Dinitrophenoxy))benzothiazole as a probe reacts with hydrogen sulfide as a relationship between fluorescence intensity change and time
(1)预先准备99μl代谢反应体系,包括pH7.4的PBS缓冲液(10mM):二甲基亚砜(体积比7:3),硫化氢(200μM),于37℃条件下反应30分钟;(1) Prepare 99 μl metabolic reaction system in advance, including PBS buffer (10 mM) at pH 7.4: dimethyl sulfoxide (volume ratio 7:3), hydrogen sulfide (200 μM), and react at 37°C for 30 minutes;
(2向反应体系中加入1μl终浓度为10μM2-(2(2,4-二硝基苯氧基))苯并噻唑起始反应;(2) Add 1 μl of 2-(2(2,4-dinitrophenoxy))benzothiazole at a final concentration of 10 μM to the reaction system to initiate the reaction;
(3)30min后,进行荧光检测(λEx=300nm,λEm=458nm);计算各体系中荧光强度,建立荧光强度与硫化氢反应时间线性关系曲线(见图6)。(3) After 30 minutes, perform fluorescence detection (λ Ex =300nm, λ Em =458nm); calculate the fluorescence intensity in each system, and establish a linear relationship curve between fluorescence intensity and hydrogen sulfide reaction time (see Figure 6).
实施例5定量测定人肺腺癌A549细胞中硫化氢含量Example 5 Quantitative determination of hydrogen sulfide content in human lung adenocarcinoma A549 cells
(1)人肺腺癌A549细胞系培养于盖玻片上,采用的培养基是DMEM培养基(含10%小牛血清)以及100μg/ml的双抗,培养环境为37℃的5%二氧化碳培养箱中;(1) The human lung adenocarcinoma A549 cell line was cultured on coverslips, the medium used was DMEM medium (containing 10% calf serum) and 100 μg/ml double antibody, and the culture environment was 5% carbon dioxide culture at 37°C in the box;
(2)使用之前,贴壁细胞采用不含血清的DMEM培养基冲洗3次,加入终浓度为10μM的2-(2(2,4-二硝基苯氧基))苯并噻唑,于37℃温孵40分钟;(2) Before use, the adherent cells were washed with serum-free DMEM medium for 3 times, and 2-(2(2,4-dinitrophenoxy))benzothiazole was added at a final concentration of 10 μM, at 37 Incubate at ℃ for 40 minutes;
(3)之后,采用PBS缓冲液冲洗3次。在激光共聚焦显微镜下观察细胞,通过荧光分布位置与强度来显示细胞中含量(见图7)。(3) After that, wash with PBS buffer 3 times. Observe the cells under a laser confocal microscope, and display the content in the cells through the fluorescence distribution position and intensity (see Figure 7).
实施例6定量测定人血中硫化氢含量Embodiment 6 Quantitative determination of hydrogen sulfide content in human blood
(1)向380μl的经PBS:二甲基亚砜溶液(体积比7:3)稀释的10%正常人血浆中加入20μl最终硫化氢浓度分别为0μM、50μM、100μM、150μM、200μM、250μM、300μM硫化氢溶液;(1) Add 20 μl to 380 μl of 10% normal human plasma diluted with PBS: dimethyl sulfoxide solution (volume ratio 7:3) and add 20 μl of final hydrogen sulfide concentrations of 0 μM, 50 μM, 100 μM, 150 μM, 200 μM, 250 μM, 300μM hydrogen sulfide solution;
(2)向反应体系中加入1μl终浓度为10μM2-(2(2,4-二硝基苯氧基))苯并噻唑起始反应;(2) Add 1 μl of 2-(2(2,4-dinitrophenoxy))benzothiazole at a final concentration of 10 μM to the reaction system to initiate the reaction;
(3)进行荧光检测(λEx=300nm,λEm=458nm);计算信噪比S/N>10,检测不同硫化氢含量血浆中荧光强度信号。(3) Perform fluorescence detection (λ Ex =300nm, λ Em =458nm); calculate the signal-to-noise ratio S/N>10, and detect the fluorescence intensity signals in plasma with different hydrogen sulfide contents.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410179994.8A CN103923640B (en) | 2014-04-30 | 2014-04-30 | A kind of fluorescence probe and application thereof of benzothiazoles identification hydrogen sulfide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410179994.8A CN103923640B (en) | 2014-04-30 | 2014-04-30 | A kind of fluorescence probe and application thereof of benzothiazoles identification hydrogen sulfide |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103923640A CN103923640A (en) | 2014-07-16 |
CN103923640B true CN103923640B (en) | 2016-05-25 |
Family
ID=51142042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410179994.8A Withdrawn - After Issue CN103923640B (en) | 2014-04-30 | 2014-04-30 | A kind of fluorescence probe and application thereof of benzothiazoles identification hydrogen sulfide |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103923640B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104479669A (en) * | 2014-11-18 | 2015-04-01 | 辽宁大学 | Preparation method and applications of enhanced type fluorescent probe for detecting hydrogen sulfide |
CN104449677B (en) * | 2014-12-29 | 2017-02-22 | 大连理工常熟研究院有限公司 | Specific fluorescent probe for recognizing fluorine ions and application of specific fluorescent probe |
CN105086995A (en) * | 2015-05-21 | 2015-11-25 | 湖南城市学院 | Preparation and Application of a H2S Probe Based on Protection and Deprotection Mechanism |
CN106083760B (en) * | 2016-02-16 | 2018-09-14 | 中国科学院理化技术研究所 | Fluorescent chemical sensor capable of selectively detecting hydrogen sulfide, preparation method and application |
CN106496217A (en) * | 2016-10-31 | 2017-03-15 | 湖南师范大学 | Preparation method and application of a novel fluorescent molecular probe for detecting H2S |
CN107782707B (en) * | 2017-10-12 | 2020-07-17 | 华南师范大学 | Application of triphenylthiazolyl benzene in fluorescence detection of nitro aromatic explosives |
CN111072650B (en) * | 2018-10-22 | 2021-04-06 | 北京工商大学 | Benzothiazole hydrogen sulfide fluorescent probe |
CN111116433A (en) * | 2018-10-31 | 2020-05-08 | 北京工商大学 | A dual recognition site hydrogen sulfide fluorescent probe |
CN112876425B (en) * | 2021-02-06 | 2022-05-06 | 许昌学院 | A kind of hydrogen sulfide fluorescent probe and preparation method and application thereof |
CN115160237A (en) * | 2022-08-03 | 2022-10-11 | 王威 | Fluorescent probe for detecting hydrogen sulfide and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0476457A2 (en) * | 1990-09-19 | 1992-03-25 | Bayer Corporation | 2-Benzothiazolyl tetrazolium salt indicators |
CN101250405A (en) * | 2008-02-26 | 2008-08-27 | 南京大学 | A Novel Thiol Fluorescent Probe and Its Application |
CN102250134A (en) * | 2010-05-21 | 2011-11-23 | 中国科学院化学研究所 | Fluorescent probe for identifying fluorine ions and preparation method and use thereof |
CN103351335A (en) * | 2013-05-28 | 2013-10-16 | 中南大学 | Synthesis of fluorescence enhanced fluorescent molecular probe for detecting mercapto-containing amino acids, and application of probe |
-
2014
- 2014-04-30 CN CN201410179994.8A patent/CN103923640B/en not_active Withdrawn - After Issue
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0476457A2 (en) * | 1990-09-19 | 1992-03-25 | Bayer Corporation | 2-Benzothiazolyl tetrazolium salt indicators |
CN101250405A (en) * | 2008-02-26 | 2008-08-27 | 南京大学 | A Novel Thiol Fluorescent Probe and Its Application |
CN102250134A (en) * | 2010-05-21 | 2011-11-23 | 中国科学院化学研究所 | Fluorescent probe for identifying fluorine ions and preparation method and use thereof |
CN103351335A (en) * | 2013-05-28 | 2013-10-16 | 中南大学 | Synthesis of fluorescence enhanced fluorescent molecular probe for detecting mercapto-containing amino acids, and application of probe |
Non-Patent Citations (3)
Title |
---|
"2- ( 2 - 羟基苯基 ) 苯并噻唑的合成及荧光性能研究";陈明强.;《中国矿业大学学报》;20020531;第31卷(第3期);第319-322页 * |
"A highly selective fluorescent probe for fast detection of hydrogen sulfide in aqueous solution and living cells";Z. Xu et al.,;《Chem. Commun》;20120914;第48卷(第88期);第10871-10873页 * |
"Selective fluorometric detection of aromatic thiols by a chemosensor containing two electrophilic sites with different local softness";Y. Shiraishi et al.,;《Chem. Commun》;20131022;第49卷(第99期);第11680-11682页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103923640A (en) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103923640B (en) | A kind of fluorescence probe and application thereof of benzothiazoles identification hydrogen sulfide | |
CN103755672B (en) | A kind of specificity fluorescent probe for identifying cysteine and application thereof | |
CN104531136B (en) | A specific fluorescent probe for identifying thiophenol and its application | |
Zhao et al. | Dicyanoisophorone-based near-infrared-emission fluorescent probe for detecting NAD (P) H in living cells and in vivo | |
Shamsipur et al. | Indirect colorimetric detection of glutathione based on its radical restoration ability using carbon nanodots as nanozymes | |
Jun et al. | “Turn-on” fluorescent sensing with “reactive” probes | |
Zhu et al. | A highly selective colorimetric probe for fast and sensitive detection of hypochlorite in absolute aqueous solution | |
Nie et al. | Dual-site fluorescent probe to monitor intracellular nitroxyl and GSH-GSSG oscillations | |
Liu et al. | Iminocoumarin-based fluorescence probe for intracellular H2O2 detection with a red emission and a large Stokes shift | |
CN110204536A (en) | It is a kind of for distinguish detection Cys/Hcy and GSH fluorescence probe and preparation method thereof | |
Guan et al. | Heparin-MPA dual modified CdS quantum dots used as a simple and rapid label-free fluorescent sensor for protamine and hemin detection | |
Liu et al. | An “off− on” NIR fluorescence probe for visualization of H2S in food spoilage, living cells and zebrafish | |
Liu et al. | A fluorescence turn-on probe for cysteine and homocysteine based on thiol-triggered benzothiazolidine ring formation | |
CN107216270A (en) | A kind of application for detecting hydrogen sulfide high selectivity response type fluorescence probe | |
Fang et al. | A fluorescent probe for carbon monoxide based on allyl ether rather than allyl ester: A practical strategy to avoid the interference of esterase in cell imaging | |
CN104120164A (en) | Specific fluorescence probe substrates of human carboxylesterase 2 and application thereof | |
Bretón-Romero et al. | Hydrogen peroxide signaling mediator in the activation of p38 MAPK in vascular endothelial cells | |
Sun et al. | A mitochondria-targeted ratiometric fluorescence probe for detection of SO2 derivatives in living cells | |
Chen et al. | A 3-(2′-nitro vinyl)-4-phenylselenyl coumarin as a fluorescent probe for distinguishing detection of Cys/Hcy and GSH | |
CN103242306B (en) | A kind of bacterium nitroreduction enzyme detection kit and special fluorescent probe thereof | |
Huang et al. | Elevated hypochlorous acid levels in asthmatic mice were disclosed by a near-infrared fluorescence probe | |
Jiang et al. | Bioluminescent probe for detecting mercury (II) in living mice | |
Yagishita et al. | Amino BODIPY-based blue fluorescent probes for aldehyde dehydrogenase 1-expressing cells | |
Sun et al. | A cyanine derivative-based NIR fluorescent probe for hydrogen sulfide bioimaging and food spoilage monitoring | |
Ma et al. | Rapid detection of thioredoxin reductase with a fluorescent probe via a Tag-Sec method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
AV01 | Patent right actively abandoned |
Granted publication date: 20160525 Effective date of abandoning: 20241020 |
|
AV01 | Patent right actively abandoned |
Granted publication date: 20160525 Effective date of abandoning: 20241020 |
|
AV01 | Patent right actively abandoned | ||
AV01 | Patent right actively abandoned |